AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
A tissue membrane is a thin layer or sheet of cells that covers the outside of the body (for example, skin), the organs (for example, pericardium), internal passageways that lead to the exterior of the body (for example, mucosa of stomach), and the lining of the moveable joint cavities. There are two basic types of tissue membranes: connective tissue and epithelial membranes.
=== 1950s–1960s === Bodybuilding became more popular in the 1950s and 1960s with the emergence of strength and gymnastics champions, and the simultaneous popularization of bodybuilding magazines, training principles, nutrition for bulking up and cutting down, the use of protein and other food supplements, and the opportunity to enter physique contests. The number of bodybuilding organizations grew, and most notably the International Federation of Bodybuilders (IFBB) was founded in 1946 by Canadian brothers Joe and Ben Weider. Other bodybuilding organizations included the Amateur Athletic Union (AAU), National Amateur Bodybuilding Association (NABBA), and the World Bodybuilding Guild (WBBG). Consequently, the contests grew both in number and in size. Besides the many "Mr. XXX" (insert town, city, state, or region) championships, the most prestigious titles were Mr. America, Mr. World, Mr. Universe, Mr. Galaxy, and ultimately Mr. Olympia, which was started in 1965 by the IFBB and is now considered the most important bodybuilding competition in the world. During the 1950s, the most successful and most famous competing bodybuilders were Bill Pearl, Reg Park, Leroy Colbert, and Clarence Ross. Certain bodybuilders rose to fame thanks to the relatively new medium of television, as well as cinema. The most notable were Jack LaLanne, Steve Reeves, Reg Park, and Mickey Hargitay.
=== May 2009 === On 18 May 2009, the SENSEX surged up 2,110.79 points to close at 14,285.21, from its previous closing of 12,174.42, for its largest single day rally. Less than a month later, on 4 June 2009, the SENSEX would cross the 15,000 mark. However, the SENSEX remained volatile during the summer of 2009. The SENSEX plunged by 869.65 points on 6 July 2009, the day of Union Budget presentation in Parliament on concerns over high fiscal deficit. This was the biggest Budget-day loss for the index. On 17 August 2009, the SENSEX lost 626.71 points. Once again, the SENSEX would recover from the volatility. On 7 September 2009, the SENSEX crossed the 16,000 mark, closing at 16,016.32 points. The index would gain 3,000 points over the next 12 months, as the SENSEX crossed the 19,000 mark on 13 September 2010, closing at 19,208.33 points.
Sources: en.wikipedia.org
The slide shows at (1) an epithelial cell infected by Chlamydia pneumoniae; their inclusion bodies shown at (3); an uninfected cell shown at (2) and (4) showing the difference between an infected cell nucleus and an uninfected cell nucleus. Epithelium grown in culture can be identified by examining its morphological characteristics. Epithelial cells tend to cluster together, and have a "characteristic tight pavement-like appearance". But this is not always the case, such as when the cells are derived from a tumor. In these cases, it is often necessary to use certain biochemical markers to make a positive identification. The intermediate filament proteins in the cytokeratin group are almost exclusively found in epithelial cells, so they are often used for this purpose. Cancers originating from the epithelium are classified as carcinomas. In contrast, sarcomas develop in connective tissue. When epithelial cells or tissues are damaged from cystic fibrosis, sweat glands are also damaged, causing a frosty coating of the skin.
Eighteen isotopes and four nuclear isomers are known for einsteinium, with mass numbers 240–257. All are radioactive; the most stable one, 252Es, has half-life 471.7 days. The next most stable isotopes are 254Es (half-life 275.7 days), 255Es (39.8 days), and 253Es (20.47 days). All the other isotopes have half-lives shorter than 40 hours, most shorter than 30 minutes. Of the five isomers, the most stable is 254mEs with a half-life of 39.3 hours.
=== Parts and cleavages === Transcript variant 1 of PIDD1 mRNA in humans, produces a full-length PIDD1 protein consisting of 910 amino acids, with a molecular weight of about 100 kDa. This protein can be broken down into three parts: a 48 kDa N-terminal fragment called PIDD-N, and two C-terminal fragments, PIDD-C (51 kDa) and PIDD-CC (37 kDa). These cleavages occur at positions S446 and S588 through an autoproteolytic process that resembles proteins like inteins or nucleoporin Nup98 undergo self-cleavage. These proteins contain a conserved HSF tripeptide framework that enables a hydrophilic attack of the hydroxyl-group within the serine residue on the preceding peptide bond, converting it into an ester bond that is susceptible to cleavage by an additional nucleophile. The cleavage of full-length PIDD1 (FL-PIDD1) into PIDD-C or PIDD-CC seems to occur constitutively, meaning it happens regularly, which makes FL-PIDD1 levels remain low even when p53 is activated. However, the observation that PIDD-C accumulates before PIDD-CC in response to DNA damage supports the idea that PIDD-C is the primary form generated from FL-PIDD1.
=== Replacement === From 2008, operations have experimentally replaced tracheas, with those grown from stem cells, or with synthetic substitutes, however this is regarded as experimental and there is no standardised method. Difficulties with ensuring adequate blood supply to the replaced trachea is considered a major challenge to any replacement. Additionally, no evidence has been found to support the placement of stem cells taken from bone marrow on the trachea as a way of stimulating tissue regeneration, and such a method remains hypothetical. In January 2021, surgeons at Mount Sinai Hospital in New York performed the first complete trachea transplantation. The 18-hour procedure included harvesting a trachea from a donor and implanting it in the patient, connecting numerous veins and arteries to provide sufficient blood flow to the organ.
Sources: en.wikipedia.org
Oxymatrine (matrine oxide, matrine N-oxide, matrine 1-oxide) is one of many quinolizidine alkaloid compounds extracted from the root of Sophora flavescens, a Chinese herb. It is very similar in structure to matrine, which has one less oxygen atom, and oxymatrine is partially metabolized to matrine in the human gut. Oxymatrine has a variety of effects in vitro and in animal models, including protection against apoptosis, tumor and fibrotic tissue development, and inflammation. Furthermore, oxymatrine has been shown to decrease cardiac ischemia (decreased blood perfusion), myocardial injury, arrhythmias (irregular heartbeats), and improve heart failure by increasing cardiac function.
== Rhodes Scholar == Florey decided to pursue medical research, a speciality that required study overseas. In August 1920, he applied for a Rhodes Scholarship to pursue his studies at the University of Oxford in England. His selection as the successful candidate for South Australia was announced on 8 December. This was a high honour, and came with a stipend of £300 (equivalent to $47,000 in 2022). The Rhodes Committee wanted him to commence in October, the start of the academic year at Oxford. This meant either postponing his scholarship for a year or deferring his final qualifying examinations for his medical degrees until he returned. Florey insisted that he would do neither; he would take his examinations and start at Oxford at the commencement of the Hilary term in January 1922. With the aid of the Governor of South Australia, Sir Archibald Weigall, Florey won the argument. He passed his examinations with second-class honours, and he was awarded his Bachelor of Medicine, Bachelor of Surgery degree in absentia in December 1921. During the summer break he went to Broken Hill Hospital, where he worked as a clinical assistant. On 11 December 1921, Florey embarked for England from Port Adelaide on the SS Otira, an ocean liner of the Shaw, Savill & Albion Line, travelling for free as the ship's surgeon. The ship reached Hull on 24 January 1922, and Florey took a train to London, where his sister Anne met him at King's Cross Station. Two days later he left for Oxford, where he met with the Secretary of the Rhodes Trust, Francis James Wylie.
Years after the conference, people ascribed a large amount of significance to it. According to Paul Berg and Maxine Singer in 1995, the conference marked the beginning of an exceptional era for both science and the public discussion of science policy. The guidelines devised by the conference enabled scientists to conduct experiments with recombinant DNA technology, which by 1995 dominated biological research. This research, in turn, increased knowledge about fundamental life processes, such as the cell cycle. Additionally, the conference, along with public debates on recombinant DNA, increased public interest in biomedical research and molecular genetics. For this reason, by 1995, genetics and its vocabulary had become a part of the daily press and television news. This, in turn, stimulated knowledgeable public discussion about some of the social, political, and environmental issues that emerged from genetic medicine and the use of genetically modified plants in agriculture. Another significant outcome of the conference was the precedent it set about how to respond to changes in scientific knowledge. According to the conference, the proper response to new scientific knowledge was to develop guidelines that governed how to regulate it.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.